![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
PHARMACOKINETICS OF SIMEPREVIR, JNJ-56914845 AND
RITONAVIR-BOOSTED TMC647055 WHEN CO-ADMINISTERED IN HEALTHY VOLUNTEERS
|
|
|
Reported by Jules Levin
15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. Washington DC, May 19-21, 2014
T.N. Kakuda,1 K. Spittaels,2 R. Verloes,2 I. Vanwelkenhuysen,3 C. Truyers,2 P. Van Remoortere1
1Janssen Research & Development LLC, Titusville, NJ, USA; 2Janssen Infectious Diseases, BVBA, Beerse, Belgium; 3Janssen Research & Development NV, Beerse, Belgium
![Pharm1.gif](../images/052214/052214-4/Pharm1.gif)
![Pharm2.gif](../images/052214/052214-4/Pharm2.gif)
![Pharm3.gif](../images/052214/052214-4/Pharm3.gif)
![Pharm4.gif](../images/052214/052214-4/Pharm4.gif)
![Pharm5.gif](../images/052214/052214-4/Pharm5.gif)
![Pharm6.gif](../images/052214/052214-4/Pharm6.gif)
![Pharm7.gif](../images/052214/052214-4/Pharm7.gif)
![Pharm8.gif](../images/052214/052214-4/Pharm8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|